⁶²Cu-Diacetyl-Bis (N⁴-Methylthiosemicarbazone) PET in Human Gliomas: Comparative Study with [¹⁸F]Fluorodeoxyglucose and L-Methyl-[¹¹C]Methionine PET

References

1. 1.↵
   1. Louis DN,
   2. Ohgaki H,
   3. Wiestler OD,
   4. et al

   . The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 2007;114:97–109

   CrossRefPubMedWeb of Science
2. 2.↵
   1. Plathow C,
   2. Weber WA

   . Tumor cell metabolism imaging. J Nucl Med 2008;49 Suppl 2:43S–63S

   Abstract/FREE Full Text
3. 3.↵
   1. Nariai T,
   2. Tanaka Y,
   3. Wakimoto H,
   4. et al

   . Usefulness of L-[methyl-11C] methionine-positron emission tomography as a biological monitoring tool in the treatment of glioma. J Neurosurg 2005;103:498–507

   CrossRefPubMedWeb of Science
4. 4.↵
   1. Kato T,
   2. Shinoda J,
   3. Nakayama N,
   4. et al

   . Metabolic assessment of gliomas using 11C-methionine, [18F] fluorodeoxyglucose, and 11C-choline positron-emission tomography. AJNR Am J Neuroradiol 2008;29:1176–82

   Abstract/FREE Full Text
5. 5.↵
   1. Delbeke D,
   2. Meyerowitz C,
   3. Lapidus RL,
   4. et al

   . Optimal cutoff levels of F-18 fluorodeoxyglucose uptake in the differentiation of low-grade from high-grade brain tumors with PET. Radiology 1995;195:47–52

   PubMed
6. 6.↵
   1. Miwa K,
   2. Shinoda J,
   3. Yano H,
   4. et al

   . Discrepancy between lesion distributions on methionine PET and MR images in patients with glioblastoma multiforme: insight from a PET and MR fusion image study. J Neurol Neurosurg Psychiatry 2004;75:1457–62

   Abstract/FREE Full Text
7. 7.↵
   1. Padma MV,
   2. Said S,
   3. Jacobs M,
   4. et al

   . Prediction of pathology and survival by FDG PET in gliomas. J Neurooncol 2003;64:227–37

   CrossRefPubMed
8. 8.↵
   1. Singhal T,
   2. Narayanan TK,
   3. Jacobs MP,
   4. et al

   . 11C-methionine PET for grading and prognostication in gliomas: a comparison study with 18F-FDG PET and contrast enhancement on MRI. J Nucl Med 2012;53:1709–15

   Abstract/FREE Full Text
9. 9.↵
   1. Kracht LW,
   2. Miletic H,
   3. Busch S,
   4. et al

   . Delineation of brain tumor extent with [11C]L-methionine positron emission tomography: local comparison with stereotactic histopathology. Clin Cancer Res 2004;10:7163–70

   Abstract/FREE Full Text
10. 10.↵
    1. Jensen RL

    . Brain tumor hypoxia: tumorigenesis, angiogenesis, imaging, pseudoprogression, and as a therapeutic target. J Neurooncol 2009;92:317–35

    CrossRefPubMed
11. 11.↵
    1. Cher LM,
    2. Murone C,
    3. Lawrentschuk N,
    4. et al

    . Correlation of hypoxic cell fraction and angiogenesis with glucose metabolic rate in gliomas using 18F-fluoromisonidazole, 18F-FDG PET, and immunohistochemical studies. J Nucl Med 2006;47:410–18

    Abstract/FREE Full Text
12. 12.↵
    1. Hirata K,
    2. Terasaka S,
    3. Shiga T,
    4. et al

    . (18)F-Fluoromisonidazole positron emission tomography may differentiate glioblastoma multiforme from less malignant gliomas. Eur J Nucl Med Mol Imaging 2012;39:760–70

    CrossRefPubMed
13. 13.↵
    1. Kawai N,
    2. Maeda Y,
    3. Kudomi N,
    4. et al

    . Correlation of biological aggressiveness assessed by 11C-methionine PET and hypoxic burden assessed by 18F-fluoromisonidazole PET in newly diagnosed glioblastoma. Eur J Nucl Med Mol Imaging 2011;38:441–50

    CrossRefPubMed
14. 14.↵
    1. Tateishi K,
    2. Tateishi U,
    3. Sato M,
    4. et al

    . Application of ⁶²Cu-diacetyl-bis (N4-methylthiosemicarbazone) PET imaging to predict highly malignant tumor grades and hypoxia-inducible factor-1α expression in patients with glioma. AJNR Am J Neuroradiol 2013;34:92–99

    Abstract/FREE Full Text
15. 15.↵
    1. Minagawa Y,
    2. Shizukuishi K,
    3. Koike I,
    4. et al

    . Assessment of tumor hypoxia by 62Cu-ATSM PET/CT as a predictor of response in head and neck cancer: a pilot study. Ann Nucl Med 2011;25:339–45

    CrossRefPubMed
16. 16.↵
    1. Morooka M,
    2. Kubota K,
    3. Kadowaki H,
    4. et al

    . 11C-methionine PET of acute myocardial infarction. J Nucl Med 2009;50:1283–87

    Abstract/FREE Full Text
17. 17.↵
    1. Bowen SR,
    2. van der Kogel AJ,
    3. Nordsmark M,
    4. et al

    . Characterization of positron emission tomography hypoxia tracer uptake and tissue oxygenation via electrochemical modeling. Nucl Med Biol 2011;38:771–80

    CrossRefPubMed
18. 18.↵
    1. Fujibayashi Y,
    2. Taniuchi H,
    3. Yonekura Y,
    4. et al

    . Copper-62-ATSM: a new hypoxia imaging agent with high membrane permeability and low redox potential. J Nucl Med 1997;38:1155–60

    Abstract/FREE Full Text
19. 19.↵
    1. Lewis JS,
    2. Sharp TL,
    3. Laforest R,
    4. et al

    . Tumor uptake of copper-diacetyl-bis(N(4)-methylthiosemicarbazone): effect of changes in tissue oxygenation. J Nucl Med 2001;42:655–61

    Abstract/FREE Full Text
20. 20.↵
    1. Lewis JS,
    2. McCarthy DW,
    3. McCarthy TJ,
    4. et al

    . Evaluation of 64Cu-ATSM in vitro and in vivo in a hypoxic tumor model. J Nucl Med 1999;40:177–83

    Abstract/FREE Full Text
21. 21.↵
    1. Ke Q,
    2. Costa M

    . Hypoxia-inducible factor-1 (HIF-1). Mol Pharmacol 2006;70:1469–80

    Abstract/FREE Full Text
22. 22.↵
    1. Christian N,
    2. Deheneffe S,
    3. Bol A,
    4. et al

    . Is (18)F-FDG a surrogate tracer to measure tumor hypoxia? Comparison with the hypoxic tracer (14)C-EF3 in animal tumor models. Radiother Oncol 2010;97:183–88

    CrossRefPubMedWeb of Science
23. 23.↵
    1. Lohith TG,
    2. Kudo T,
    3. Demura Y,
    4. et al

    . Pathophysiologic correlation between 62Cu-ATSM and 18F-FDG in lung cancer. J Nucl Med 2009;50:1948–53

    Abstract/FREE Full Text
24. 24.↵
    1. Oh M,
    2. Tanaka T,
    3. Kobayashi M,
    4. et al

    . Radio-copper-labeled Cu-ATSM: an indicator of quiescent but clonogenic cells under mild hypoxia in a Lewis lung carcinoma model. Nucl Med Biol 2009;36:419–26

    CrossRefPubMed
25. 25.↵
    1. Frezza C,
    2. Zheng L,
    3. Tennant DA,
    4. et al

    . Metabolic profiling of hypoxic cells revealed a catabolic signature required for cell survival. PLoS One 2011;6:e24411

    CrossRefPubMed
26. 26.↵
    1. Nehmeh SA,
    2. Lee NY,
    3. Schroder H,
    4. et al

    . Reproducibility of intratumor distribution of (18)F-fluoromisonidazole in head and neck cancer. Int J Radiat Oncol Biol Phys 2008;70:235–42

    CrossRefPubMed
27. 27.↵
    1. Behin A,
    2. Hoang-Xuan K,
    3. Carpentier AF,
    4. et al

    . Primary brain tumours in adults. Lancet 2003;361:323–31

    CrossRefPubMedWeb of Science
28. 28.↵
    1. Kayama T,
    2. Yoshimoto T,
    3. Fujimoto S,
    4. et al

    . Intratumoral oxygen pressure in malignant brain tumor. J Neurosurg 1991;74:55–59

    CrossRefPubMedWeb of Science